Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $70

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price target from $71 to $70.
byBenzinga Newsdesk
August 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price target from $71 to $70.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0